KRAS and neoplasm: Both miR-137 and Myc have been identified as possible therapeutic targets, but no studies have reported Myc as a direct target of miR-137 in humans and Drosophila. Interestingly, in a cohort of 706 patients with high KRAS expression and SCRIB loss, 395 patients (56%) exhibited low copy number expression (log2≤−0.12) of miR-137/5p, suggesting a significant heterozygous loss that may further affect the tumor-suppressive activity of miR-137 (Cerami et al., 2012; de Bruijn et al., 2023; Gao et al., 2013).